Technology area
Biologic therapeutic
651 funded awards, $428.0M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| CA (NCI) | National Cancer Institute | 147 | $665,000 |
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 146 | $303,731 |
| GM (NIGMS) | National Institute of General Medical Sciences | 82 | $381,447 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 76 | $886,839 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 39 | $590,935 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 37 | $961,962 |
| AG (NIA) | National Institute on Aging | 25 | $478,280 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 21 | $350,000 |
| EY (NEI) | National Eye Institute | 20 | $718,983 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 19 | $298,915 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 12 | $824,052 |
| HG (NHGRI) | National Human Genome Research Institute | 8 | $712,876 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 4 | $605,404 |
| EB (NIBIB) | National Institute of Biomedical Imaging and Bioengineering | 4 | $303,195 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 4 | $312,312 |
| MH (NIMH) | National Institute of Mental Health | 3 | $300,000 |
| DA (NIDA) | National Institute on Drug Abuse | 2 | $349,401 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 1 | $257,312 |
| MD (NIMHD) | National Institute on Minority Health and Health Disparities | 1 | $406,500 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-22-176 | unknown | 159 |
| PA-23-230 | unknown | 111 |
| PA-21-259 | unknown | 78 |
| PA-24-245 | unknown | 60 |
| PA-22-178 | unknown | 44 |
| PA-23-232 | unknown | 30 |
| PA-21-262 | unknown | 22 |
| PA-24-247 | unknown | 18 |
| PA-20-260 | unknown | 18 |
| PA-20-265 | unknown | 11 |
| PAS-22-196 | unknown | 8 |
| PA-23-231 | unknown | 8 |
| PA-19-272 | unknown | 8 |
| PA-20-272 | unknown | 7 |
| PAS-22-197 | unknown | 6 |
| PA-20-047 | unknown | 6 |
| PA-21-260 | unknown | 5 |
| PA-22-177 | unknown | 5 |
| PA-24-246 | unknown | 4 |
| PA-21-345 | unknown | 3 |
| RFA-HL-23-008 | unknown | 2 |
| RFA-CA-23-034 | unknown | 2 |
| RFA-CA-24-023 | unknown | 2 |
| RFA-AG-24-042 | unknown | 2 |
| RFA-CA-23-035 | unknown | 2 |
| PA-25-212 | unknown | 2 |
| RFA-CA-21-001 | unknown | 2 |
| PA-19-271 | unknown | 2 |
| PAR-21-030 | unknown | 2 |
| PAR-21-114 | unknown | 2 |
| PAR-22-073 | unknown | 2 |
| PAS-19-317 | unknown | 2 |
| PA-18-574 | unknown | 2 |
| PA-20-262 | unknown | 2 |
| RFA-MD-24-007 | unknown | 1 |
| RFA-NS-23-006 | unknown | 1 |
| PAR-24-131 | expired | 1 |
| RFA-MD-23-003 | unknown | 1 |
| RFA-DA-24-018 | unknown | 1 |
| RFA-NS-20-010 | unknown | 1 |
| PA-17-302 | unknown | 1 |
| RFA-HL-19-017 | unknown | 1 |
| RFA-NS-20-009 | unknown | 1 |
| RFA-NS-20-011 | unknown | 1 |
| PAR-21-247 | unknown | 1 |
| RFA-CA-20-033 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10598447 | 2025 | CA | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | FANNIN PARTNERS, LLC | $999,997 |
| 10850989 | 2025 | CA | CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | ROCK IMMUNE, INC. | $248,336 |
| 10932102 | 2025 | NS | Next-generation nanomedicine for acute ischemic stroke | NANOMUSE, LLC | $351,461 |
| 10935988 | 2025 | AR | Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis | PROVIZIGEN LLC | $158,663 |
| 10997344 | 2025 | AI | A Vaccine for Lymphatic Filariasis, LFGuard™ | PAI LIFE SCIENCES, INC. | $452,996 |
| 11003734 | 2025 | AI | Chikungunya Recombinant Subunit Vaccine | HAWAII BIOTECH, INC. | $998,229 |
| 11010813 | 2025 | AI | Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. | TRACE-ABILITY, INC. | $1,000,000 |
| 11014847 | 2025 | GM | Combinatorial pipeline for discovery of anti-GPCR Nanobodies | BIOCOGNON LLC | $303,024 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'biologic_therapeutic' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
Biologic therapeutic activity in NIH SBIR sits almost evenly across NCI (147) and NIAID (146). NCI's slice covers antibody, ADC, and CAR-T work; NIAID skews toward antibody platforms for infectious disease and vaccine-adjacent biologics. NIGMS at 82 captures the basic-mechanism work. The mechanism mix is heavily R44 (325) with a solid R43 (179) base, and the R41 footprint is unusually large at 93, since biologics development is one of the tags where academic-IP origins remain common. Median award is $500K. Recipient concentration is low at 4%, so no single firm has cornered the dataset. The tag bundles monoclonals, fusion proteins, CAR-T, ADCs, and recombinant proteins, so a single number flattens a lot of underlying heterogeneity.
Fit indicators
Watchouts